The U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of Evrysdi (risdiplam), an approved oral ...

The last 18 months have been a whirlwind for Lindsay Carter and the business she founded, owns and serves as clinical ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

Therapist Katharine Mackenzie Paterson works from a beautiful Georgian townhouse in Mayfair, with a plush treatment room that feels pampering just to look at. Her heavenly bespoke facials combine ...

A "groundbreaking" £1.65 million treatment has been approved for use on the NHS, offering patients with severe sickle cell disease some hope of a cure. It is believed around 1,700 people could be ...

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t working, but it’s not ...

For treatment-resistant depression, patients usually get the esketamine nasal spray twice ... The doctor isn’t necessarily in the room with the person being treated but is available if they ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now. Federal regulators approved Johnson & Johnson’s (NYSE: JNJ) nasal ...

patients will start getting relief from the esketamine treatment, and that relief can last to the duration study through 28 days of treatment that’s been studied here,” he added.